Aquestive Therapeutics, Inc. (AQST) News
Filter AQST News Items
AQST News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AQST News Highlights
- AQST's 30 day story count now stands at 6.
- Over the past 22 days, the trend for AQST's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about AQST are AMPH, CNTA and DEC.
Latest AQST News From Around the Web
Below are the latest news stories about AQUESTIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate AQST as an investment opportunity.
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive TherapeuticsAmphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics are part of the Zacks top Analyst Blog. |
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024. |
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year. |
Best Momentum Stock to Buy for December 7thAQST and VVI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 7, 2023. |
Syros (SYRS) Rises on Upbeat Initial Study Data on TamibaroteneSyros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia. |
Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm™ (epinephrine) Sublingual FilmCommences initial Phase 3 study with first orally delivered epinephrine prodrug candidateReaffirms topline data anticipated in first quarter 2024 WARREN, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that the first patient has been dosed in its initial Phase 3 piv |
New Strong Buy Stocks for December 1stAQST, TM, LEU, BWAY and MOD have been added to the Zacks Rank #1 (Strong Buy) List on December 1, 2023. |
Aquestive Therapeutics (AQST) Just Flashed Golden Cross Signal: Do You Buy?When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react? |
Best Momentum Stocks to Buy for November 28thAQST, FMX and MNSO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 28, 2023. |
New Strong Buy Stocks for November 28thAQST, BROS, NSSC, RIGL and RBT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2023. |